|
ApoVax™
ApoVax™ is a recombinant protein-based vaccine. The first family of the ApoVax™ products is the ApoVax104™ vaccine line. In preclinical studies, the vaccine has proven to be much more effective and less toxic than other vaccine components currently being tested in late stage clinical trials by large pharmaceutical companies.
[ more ]
ApoVax104-HPV™
ApoImmune's first product will be ApoVax104-HPV™, a proprietary therapeutic vaccine for cervical cancer in which ApoVax104™ is combined with the tumor antigen E7, a protein from the human papillomavirus (HPV) that causes cervical cancer in women. In preclinical studies, the vaccine has proven to be much more effective and less toxic than other vaccine components currently being tested in late stage clinical trials by large pharmaceutical companies.
[ more ]
ProtEx™
ApoImmune's other platform technology, ProtEx™, is a technology that enables recombinant immunoregulatory proteins to be placed on the surface of cells, tissues, organs, and synthetic surfaces in order to modulate the immune system. ProtEx™, like ApoVax™, is a recombinant protein-based vaccine therapy.
[ more ]
|
|
|
|
